Baricitinib Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19

  • STATUS
    Recruiting
  • participants needed
    144
  • sponsor
    University of Southern California
Send
Updated on 5 August 2020
See if I qualify
cancer
body mass index
antibody test
hypertension
antiviral drugs
pneumonia
antiviral therapy
PCR test
oxygen saturation
chronic disease
cough
obesity
covid-19
hydroxychloroquine
lung disease
coronavirus infection
lopinavir/ritonavir
remdesivir
acute respiratory syndrome (sars)

Summary

This phase II trial studies the effect of baricitinib in combination with antiviral therapy for the treatment of patients with moderate or severe coronavirus disease-2019 (COVID-19). Treatment with antiviral medications such as hydroxychloroquine, lopinavir/ritonavir, and/or remdesivir may act against infection caused by the virus responsible for COVID-19. Baricitinib may reduce lung inflammation. Giving baricitinib in combination with antiviral therapy may reduce the risk of the disease from getting worse and may help prevent the need for being placed on a ventilator should the disease worsen compared to antiviral therapy alone.

Description

PRIMARY OBJECTIVE:

I. To determine the efficacy of baricitinib combined with antiviral therapy in participants with COVID-19-related moderate and severe disease in terms of reduction of the proportion of participants requiring invasive mechanical ventilation or dying or requiring anti-IL6 monoclonal antibodies compared to that seen with antiviral alone within 60 days.

SECONDARY OBJECTIVES:

I. To describe the clinical findings in a cohort of symptomatic COVID-19-infected participants.

II. To test whether cytokine signatures predict progression to invasive ventilatory support or death.

III. To describe adverse events (AEs) associated with baricitinib when administered at 4mg in combination with antivirals.

EXPLORATORY OBJECTIVES:

I. Describe the decay in quantitative viral burden from saliva samples collected sequentially under treatment with baricitinib in combination with antivirals.

II. To obtain preliminary data on efficacy and tolerability of baricitinib in combination with antivirals in participants with cancer.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients receive baricitinib orally (PO) daily, and standard of care hydroxychloroquine PO three times daily (TID). Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.

GROUP II: Patients receive placebo PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.

Patients are followed for 60 days after enrollment to treatment.

Details
Condition Symptomatic COVID-19 Infection Laboratory-Confirmed
Age 18years - 100years
Treatment Hydroxychloroquine, Placebo Administration, Baricitinib
Clinical Study IdentifierNCT04373044
SponsorUniversity of Southern California
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

Positive polymerase chain reaction (PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in a respiratory tract sample OR positive anti-SARS CoV2 IgM antibody test that is approved by Food and Drug Administration (FDA) or allowed under an emergency use authorization; either result obtained within 5 days prior to study entry
Cough and/or pneumonia on chest imaging
Moderate disease with risk factor(s): Peripheral capillary oxygen saturation (SpO2) >= 92% on room air with one of the following risk factors for development of severe disease: age >= 60 years, receiving medication for hypertension, diagnosed diabetes mellitus, known cardiac disease, chronic lung disease, obesity (body mass index [BMI] >= 35 kg/m^2), active malignancy, immunosuppression (receiving biologics or glucocorticoids >= 20 mg/d prednisone equivalent for > 2 weeks)
Severe disease: SpO2 =< 92% on room air
Ability to understand and the willingness to sign a written informed consent. Adults not competent to consent will be enrolled with the use of an appropriate legally authorized representative (per California Code, Health and Safety Code - HSC)
FDA regulations generally require that the informed consent of a participant be documented by the use of a written consent form approved by the IRB and signed and dated by the participant or the participant's legally authorized representative at the time of consent (21 case form report [CFR] 50.27[a]). In light of COVID-19 infection control measures, the following procedure would satisfy documentation of this requirement if the participant signing the informed consent is in COVID-19 isolation. If the technology is available, electronic methods of obtaining informed consent will be taken. The electronic consent and Health Insurance Portability and Accountability Act (HIPAA) forms will be uploaded and available through REDCap
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 7 days following completion of therapy. NOTE: Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Women of child-bearing potential should use highly effective methods of birth control. These are those methods of contraception, alone or in combination, that result in a low failure rate (i.e, less than 1% per year) when used consistently and correctly

Exclusion Criteria

Mechanical ventilation, high-flow nasal oxygen, biphasic positive airway pressure (BiPAP)
Venous thromboembolism within 12 weeks or previously diagnosed thrombophilic conditions or conditions that increase the risk of thrombosis. Individuals with > 1 episode of venous thromboembolism or pulmonary embolism in the past will also be excluded
Prior receipt of other immunomodulatory drugs (e.g., any JAK inhibitors, immunomodulatory biologics, or other immunomodulatory investigational products) within 14 days prior to enrollment
Current treatment with probenecid
Known infection with human immunodeficiency syndrome (HIV), or active infection with hepatitis B or hepatitis C
Participant with known active or latent tuberculosis infection
Pregnancy and lactation
Any serious acute infections or known active or latent tuberculosis
All enrolled participants will be screened for latent tuberculosis infection by testing QuantiFERON-TB Gold Plus, but a documented negative test will not be required prior to entry. If a participant is found to have positive QuantiFERON that results after enrollment, baricitinib will be discontinued
Solid organ transplant recipient
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 x upper limit of normal
Absolute neutrophil count < 1000/mm^3
Absolute lymphocyte count < 200/mm^3
Hemoglobin < 8 g/dl
Estimated glomerular filtration rate (GFR) < 30 mL/min/1.73 m^2
Any medical condition in the opinion of the investigator that would place the participant at undue high risk for participation in the trial
Hypersensitivity to the active substance or to any of the excipients
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
body mass index
antibody test
hypertension
antiviral drugs
pneumonia
antiviral therapy
PCR test
oxygen saturation
chronic disease
cough
obesity
covid-19
hydroxychloroquine
lung disease
coronavirus infection
lopinavir/ritonavir
remdesivir
acute respiratory syndrome (sars)

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.